Kattan et al developed a nomogram for evaluating a man with clinically localized prostate cancer. This can be used to predict 10 year cancer-specific survival if the patient is not immediately treated with an intent to cure. The authors are from multiple hospitals in the United States and England participating in the Transatlantic Prostate Group.
Parameters:
(1) clinical T stage
(2) Gleason score
(3) specimen (needle biopsy vs TURP)
(4) early hormonal therapy
(5) age at diagnosis
(6) baseline PSA
(7) percent cancer in specimen
points for percent cancer =
= (0.372 * (percent cancer as a whole number from 0 to 100)
points for baseline PSA in ng/mL =
= (0.4 * (PSA in ng/ml))
points for age at diagnosis (over range of 44 to 76) =
= (2.654 * (age in years)) - 116.7
|
Parameter |
Finding |
Points |
|
clinical T stage |
T1 |
0 |
|
|
T2 |
19 |
|
|
T3 |
40 |
|
specimen |
TURP |
0 |
|
|
needle biopsy |
6 |
|
early hormone |
no |
0 |
|
|
yes |
26 |
|
Gleason score |
no grade 4 or 5 |
0 |
|
|
3+4 |
11 |
|
|
4+3 |
11.3 |
|
|
4+4 |
43 |
|
|
any 5 |
100 |
total score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 320
• The higher the score the lower the probability of cancer specific survival of at least 10 years (120 months)
|
Total Points |
Probability of Cancer Specific Survival of 10 Years |
|
< 3 |
> 96% |
|
3 to 222 |
(-0.001222 * ((points)^2)) + (0.02331 * (points)) + 95.49 |
|
222 to 316 |
(0.002135 * ((points)^2)) - (1.548 * (points)) + 278.5 |
|
> 316 |
< 3% |
Specialty: Hematology Oncology, Surgery, general, Urology
